<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>D-ITM29499BGADIAOPX8C</udiDi>
    <basicUdiDi>B-ITM29499BGADIAOPX8C</basicUdiDi>
    <tradeName>Lenodiar Adult</tradeName>
    <deviceName>Antidiarroico adulti</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>BGADIAOPX</reference>
    <placedOnMarketCountry>Bulgaria</placedOnMarketCountry>
    <lastUpdated>2026-07-22T00:30:34.318Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-ITM29499BGADIAOPP7U</udiDi>
    <basicUdiDi>B-ITM29499BGADIAOPP7U</basicUdiDi>
    <tradeName>Lenodiar Adult</tradeName>
    <deviceName>Antidiarroico adulti</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>BGADIAOPP</reference>
    <placedOnMarketCountry>Bulgaria</placedOnMarketCountry>
    <lastUpdated>2026-07-22T00:30:33.527Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.CAMPQY</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.CAMPQY</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.CAMP</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:32.664Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.A.C6W</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.A.C6W</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.APPLE.CAMP</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:31.915Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.300.A4G</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.300.A4G</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.300.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:31.061Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.24T5</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.24T5</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.24</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:30.263Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.24.AFU</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.24.AFU</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.24.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:26.260Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.12SW</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.12SW</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.12</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:25.454Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.12.AFB</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.12.AFB</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.12.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T21:42:24.661Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778108313</udiDi>
    <basicUdiDi>42517781MD347D7</basicUdiDi>
    <tradeName>DulcoSoft</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>909976</reference>
    <placedOnMarketCountry>Portugal</placedOnMarketCountry>
    <lastUpdated>2026-07-21T20:01:22.885Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.2.10SZ</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.2.10SZ</basicUdiDi>
    <tradeName>ALGORAL INFANT EPSILON HEALTH</tradeName>
    <deviceName>ALGORAL INFANT EPSILON HEALTH</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.2.210</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-21T19:46:44.615Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.2.210.A46</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.2.210.A46</basicUdiDi>
    <tradeName>GASTUCALM</tradeName>
    <deviceName>GASTUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.2.210.A01</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-20T20:01:58.557Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.3003X</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.3003X</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.300</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-20T19:46:20.399Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.2103V</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.2103V</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.210</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-20T19:46:09.976Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FF.1.210.A4C</udiDi>
    <basicUdiDi>B-FT.CE.107.FF.1.210.A4C</basicUdiDi>
    <tradeName>COMIL ANTIREFLUSSO</tradeName>
    <deviceName>COMIL ANTIREFLUSSO</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FF.1.210.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-20T19:46:09.230Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.1.A.C6D</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.1.A.C6D</basicUdiDi>
    <tradeName>REFLUCALM</tradeName>
    <deviceName>REFLUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.1.APPLE.CAMP</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-17T19:36:46.530Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.1.24.AF9</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.1.24.AF9</basicUdiDi>
    <tradeName>REFLUCALM</tradeName>
    <deviceName>REFLUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.1.24.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-17T19:36:45.240Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.1.CAMPQD</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.1.CAMPQD</basicUdiDi>
    <tradeName>REFLUCALM</tradeName>
    <deviceName>REFLUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.1.CAMP</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-17T02:03:18.986Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.1.300.A3R</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.1.300.A3R</basicUdiDi>
    <tradeName>REFLUCALM</tradeName>
    <deviceName>REFLUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.1.300.APPLE</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-17T02:03:15.004Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-FT.CE.107.FE.1.3003E</udiDi>
    <basicUdiDi>B-FT.CE.107.FE.1.3003E</basicUdiDi>
    <tradeName>REFLUCALM</tradeName>
    <deviceName>REFLUCALM</deviceName>
    <manufacturerName>GRUPPO FARMAIMPRESA SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000012625</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>FT.CE.107.FE.1.300</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-17T02:03:10.025Z</lastUpdated>
  </row>
</eudamedExport>